NAV
$106.85
AUM
$73.7M
Expense Ratio
-
Dividend Yield
0.00%
Beta
1.14
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +33.68% | +32.86% | +31.60% | +127.30% | +28.69% | +1.93% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | IQMM | ProShares GENIUS Money Market ETF | 6.79% |
| 2 | GILD | Gilead Sciences Inc | 4.66% |
| 3 | VRTX | Vertex Pharmaceuticals Inc | 4.65% |
| 4 | AMGN | Amgen Inc | 4.48% |
| 5 | REGN | Regeneron Pharmaceuticals Inc | 3.20% |
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Inception Date: 2010-04-06